About albutrepenonacog alfa
Recombinant factor IX fusion protein
Used for
- Prevention and treatment of bleeding in haemophilia B
- Bleeding control during and after surgery in haemophilia B
Usual adult dose
Individualized by weight, bleeding severity, and treatment goal; often 25–50 IU/kg every 7–14 days for prevention.
Usual dose in children
Individualized by weight and treatment goal; often 25–50 IU/kg every 7–14 days for prevention.
Common side effects
- Headache
- Injection-site reactions
- Rash or itching
- Development of factor IX inhibitors
Important warnings
- Severe allergic reactions can occur.
- Monitor for factor IX inhibitors, especially if bleeding control worsens.
- Use cautiously in people with liver disease or risk of blood clots.
- Not for treating haemophilia A or von Willebrand disease.
Pregnancy
Limited human data; use only when clearly needed and under specialist care.
Breastfeeding
Unknown whether it passes into breast milk; consider clinical need and specialist guidance.
Interactions
- No well-established medicine interactions; tell clinicians about all medicines and supplements.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.